期刊文献+

他克莫司血药浓度监测与合理用药分析 被引量:10

Analysis of Blood Concentration Monitoring of Tacrolimus and Rational Use of Drugs
原文传递
导出
摘要 目的:通过分析服用他克莫司(FK506)患者的全血浓度监测结果,参考有效的治疗范围,为FK506血药浓度监测及临床合理用药提供参考。方法:采用回顾性分析,以我院2011年12月-2012年12月FK506血药浓度监测的977人次为研究对象,对血药浓度监测结果正常范围的治疗效果及异常监测结果进行分析。结果:977人次中,正常、低于、高于参考范围所占的比例分别为65.5%、33.2%、1.3%。血药浓度的异常可能与患者的饮食、依从性、合并用药、血容量、监测方法及个体差异有关。FK506不良反应相对少见。结论:应用FK506时应遵循个体化用药的原则,从小剂量开始,并根据患者FK506的血药浓度、肝肾功能及机体的耐受力进行综合评估,及时调整用药。 OBJECTIVE: To provide reference for blood concentration monitoring of tacrolimus (FK506) and clinical use of drug by analyzing the blood concentration monitoring results of FK506 and referring to the effective range of treatment. METH-ODS: Blood concentration of FKS06 in 977 patients as research object was determined by retrospective method in our hospital dur- ing Dec. 2011- Dec. 2012. Therapeutic effect of normal range of blood concentration monitoring was analyzed as well as results of abnormal monitoring. RESULTS: Among 977 patients, blood concentration of FK605 which was equal to, lower than or higher than reference range accounted for 65.5%, 33.2% and 1.3%, respectively. Abnormal blood concentration may be related to the compliance of patient and drug dosage. The adverse drug reactions of FK506 was rarely found. CONCLUSIONS: FKS06 should fol-low the principle of individual medication, starting from small dose; based on the blood concentration of FK506, liver and kidney function and the body's tolerance were evaluated comprehensively to adjust medication timely.
出处 《中国药房》 CAS CSCD 2013年第26期2427-2429,共3页 China Pharmacy
关键词 他克莫司 血药浓度监测 合理用药 Tacrolimus Blood concentration monitoring Rational use of drugs
作者简介 副主任药师。研究方向:治疗药物监测。电话:0931—8994675。E—mail:xiehua-72@163.com
  • 相关文献

参考文献7

二级参考文献23

  • 1周甘平,徐峰.双环醇治疗肾移植术后肝损伤的应用[J].中国药物应用与监测,2004,1(4):7-8. 被引量:1
  • 2夏穗生.肝移植进展[J].中国普外基础与临床杂志,2005,12(2):97-99. 被引量:9
  • 3李罄,吴笑春,辛华雯,朱敏,余爱荣.联苯双酯滴丸降低肾移植受者全血环孢素A浓度[J].中华器官移植杂志,2005,26(4):243-245. 被引量:8
  • 4戴澄,王平,张清,陈伟星.不同免疫抑制方案对移植肾早期功能的影响[J].中国现代医学杂志,2006,16(21):3295-3297. 被引量:4
  • 5Bresnahan BA, Cherikh WS, Chong Y, et al. Short term benefit of tarcrolimus vs cyclosparine therapy after renal transplantation: an analysis of UNOS/OPTN datahase. Washington DC,2003.1213.
  • 6Chenhsu RY, Loong CC, Chou MH, et al. Renal allograft dysfunction associated with rifampin- tarcrolimus interaction. Ann Pharmacother, 2000,34:27.
  • 7Sewing KF. Pharmacokinetics, doing principles and blood level monitoring of FK506. Transplantat Proc, 1994, 26(6):3267.
  • 8LIU KT, CRESTEIL T, LE PROVOST E. Specific evidence that schizandrins induce a phenobarbital-like cytochrome P-450 from separated rat liver[J]. Biochem Biophys Res Commun, 1981,103 (4) : 1131 - 1137.
  • 9LIU KT, LESCA P. Pharmacological properties of dibenzo[ a,c ] cyclooctene derivatives isolated from Fructus Schizandrae chinensis. I. Interaction with rat liver cytochrome P-450 and inhibition of xenobiotic metabolism and mutagenicity [ J ]. Chem Biol Interact, 1982,39(3) :301 -314.
  • 10Yu X, Zhang B, Xing C, et al.Different effect of cyclospo- rine and tacrolimus on renal expression of P-glycoprotein in human kidney transplantation[J]. Transplant Proc, 2008,40(10) : 3 455.

共引文献896

同被引文献110

  • 1张鑫,刘志红,郑敬民,陈朝红,唐政,陈劲松,黎磊石.肾移植患者他克莫司血药浓度的影响因素[J].肾脏病与透析肾移植杂志,2005,14(4):333-338. 被引量:21
  • 2鲍浩,章海涛,张馨,胡伟新,谢红浪,陈惠萍,曾彩虹,刘志红,黎磊石.难治性狼疮性肾炎多靶点治疗前瞻性临床研究[J].肾脏病与透析肾移植杂志,2007,16(1):5-13. 被引量:35
  • 3LAMPEN A, CHRISTIANS U, GUENGERICH FP, et al. Metabolism of the immunosuppressant FK in the small intestine: cytochrome P450, drug interactions and interindividual variability[J]. Drug Metab Dispos, 1995, 23(12): 1315-1319.
  • 4Dc-Ryckc A, Dicrickx D, Kuypcrs DR. Tacrolimus induced neut-ropenia in renal transplant recipients[ J] . Clin J Am Soc Nephrol,2011,6(3):690 -694.
  • 5Ruth AL,Steven G. Current trends in immunosup-pressive therapiesfor renal transplant recipients [ J ] . Am J Health Syatpharm ,2012 ,69(15) :1961 -1975.
  • 6Mesar I, Kes P, Hudolin T, et al. Rescue therapy with sirolimus in a renal transplant recipient with tacrolimus-induced hepatotoxicity [J]. Ren Fail, 2013, 35(10): 1434-1435.
  • 7Wu P, Ni X, Wang M, et al. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients [J]. Ann Transplant, 2011, 16(1): 54-60.
  • 8Yah Y, Sun HH, Hunter DA, et al. Efficacy of short-term FK506 administration on accelerating nerve regeneration [J]. Neurorehabil Neural Repair, 2012, 26(6): 570-580.
  • 9Kidney Disease: Improving Global Outcomes (KDIGO)Transplant Work Group. KDIGO clinical practice guideline forthe care of kidney transplant recipients[J]. Am J Transplant, 2009, 9(Suppi 3): S1-S155.
  • 10Velickovi6-Radovanovi6 R, Mikov M, Paunovi6 G, et al. Gender differences in pharmacokinetics of tacfolimus and their clinical significance in kidney transplant recipients[J].Gend Med, 2011, 8(1):23-31.

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部